AN2 Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	24.69	15.65	27.22	12.1	4.07
Short-Term Investments	89.52	91.65	68.84	46.46	0
Cash & Cash Equivalents	114.21	107.3	96.06	58.56	4.07
Cash Growth	29.03%	11.70%	64.05%	1338.70%	-
Other Current Assets	2.1	3.21	2.56	1.55	0.16
Total Current Assets	116.31	110.51	98.62	60.11	4.23
Property, Plant & Equipment	0	0	0.05	0	0
Long-Term Investments	3.9	27.19	3.22	3.49	0
Other Long-Term Assets	1.04	1.04	0.67	1.72	0
Total Long-Term Assets	4.95	28.24	3.94	5.21	0
Total Assets	121.26	138.74	102.56	65.32	4.23
Accounts Payable	2.43	2.68	2.12	1.06	0.13
Current Debt	0	0	0.05	0	0
Other Current Liabilities	8.23	11.37	5.01	2.33	1.33
Total Current Liabilities	10.66	14.04	7.19	3.4	1.46
Other Long-Term Liabilities	0	0	0	0.01	0.02
Total Long-Term Liabilities	0	0	0	0.01	0.02
Total Liabilities	10.66	14.04	7.19	3.41	1.48
Total Debt	0	0	0.05	0	0
Retained Earnings	-171.07	-154.46	-89.72	-47.38	-20.32
Comprehensive Income	0.05	0.28	-0.37	-0.03	0
Shareholders' Equity	110.6	124.7	95.37	-47.41	-20.32
Net Cash / Debt	114.21	107.3	96.01	58.56	4.07
Net Cash / Debt Growth	29.08%	11.76%	63.96%	1338.70%	-
Net Cash Per Share	3.84	4.55	6.26	22.20	1.58
Working Capital	105.65	96.46	91.44	56.71	2.78
Book Value Per Share	3.72	5.28	6.22	-17.97	-7.91

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).